Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preclinical studies with toremifene as an antitumor agent.

S P Robinson1, C J Parker, V C Jordan

  • 1Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison 53792.

Breast Cancer Research and Treatment
|August 1, 1990
PubMed
Summary

Toremifene effectively inhibits estrogen-sensitive breast cancer growth in vitro and in vivo. However, it acts as a tumoristatic agent, requiring continuous treatment to prevent recurrence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effects of Menstrual Cycle Phase on Gastrointestinal Responses to a Simulated Football Match.

European journal of sport science·2026
Same author

Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial.

Bone marrow transplantation·2021
Same author

SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma.

Endocrine-related cancer·2019
Same author

Diffuse large B-cell lymphoma: the challenge of relapse after an autologous stem cell transplant.

Bone marrow transplantation·2016
Same author

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.

Disease models & mechanisms·2016
Same author

Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Toremifene is an investigational nonsteroidal antiestrogen for breast cancer treatment.
  • Estrogen receptor (ER) positive breast cancers are often hormone-dependent.

Purpose of the Study:

  • To evaluate the efficacy of toremifene in inhibiting breast cancer cell growth in vitro and in vivo.
  • To determine the mechanism of action and optimal treatment strategy for toremifene.

Main Methods:

  • In vitro studies using MCF-7 (hormone-dependent) and MDA-MB-231 (hormone-independent) breast cancer cell lines.
  • In vivo studies using athymic mouse models with MCF-7 and MDA-MB-231 xenografts.
  • Evaluation of toremifene's effect on 7,12-dimethylbenzanthracene-induced rat mammary tumors.

Main Results:

Related Experiment Videos

  • Toremifene inhibited MCF-7 cell growth in vitro and in vivo, but not MDA-MB-231 cells.
  • Toremifene significantly inhibited estradiol-stimulated MCF-7 tumor growth in mice.
  • Toremifene demonstrated preventive effects against carcinogen-induced rat mammary tumors, which were reversible upon cessation of treatment.

Conclusions:

  • Toremifene exhibits tumoristatic, not tumoricidal, activity against breast cancer.
  • Continuous toremifene treatment is crucial for managing tumor recurrence, particularly in adjuvant settings.